1. Namlos HM, Kresse SH, Muller CR, Henriksen J, Holdhus R, Saeter G, et al. Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. Sarcoma. 2012;2012:639038.
2. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18(24):4016-27.
3. Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CS. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 2017;59(1):71.
4. Lu Y, Song T, Xue X, Cao G, Huang P. Kinesin superfamily proteins: roles in osteosarcoma. Frontiers in bioscience. 2021;26(8):370-8.
5. Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer. 2005;104(5):1100-9.
6. Kelleher FC, O'Sullivan H. Monocytes, Macrophages, and Osteoclasts in Osteosarcoma. Journal of adolescent and young adult oncology. 2017;6(3):396-405.
7. Ruggieri P, Mavrogenis AF, Mercuri M. Quality of life following limb-salvage surgery for bone sarcomas. Expert review of pharmacoeconomics & outcomes research. 2011;11(1):59-73.
8. Nytko KJ, Thumser-Henner P, Russo G, Weyland MS, Rohrer Bley C. Role of HSP70 in response to (thermo)radiotherapy: analysis of gene expression in canine osteosarcoma cells by RNA-seq. Scientific reports. 2020;10(1):12779.
9. Ahmed AA, Zia H, Wagner L. Therapy resistance mechanisms in Ewing's sarcoma family tumors. Cancer chemotherapy and pharmacology. 2014;73(4):657-63.
10. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(3):776-90.
11. de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, et al. Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. Clinical sarcoma research. 2019;9:9.
12. Cotta-Ramusino C, Fachinetti D, Lucca C, Doksani Y, Lopes M, Sogo J, et al. Exo1 processes stalled replication forks and counteracts fork reversal in checkpoint-defective cells. Mol Cell. 2005;17(1):153-9.
13. Keijzers G, Bakula D, Petr MA, Madsen NGK, Teklu A, Mkrtchyan G, et al. Human Exonuclease 1 (EXO1) Regulatory Functions in DNA Replication with Putative Roles in Cancer. Int J Mol Sci. 2018;20(1).
14. Dai Y, Tang Z, Yang Z, Zhang L, Deng Q, Zhang X, et al. EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients. Cell cycle. 2018;17(19-20):2386-97.
15. Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacology & therapeutics. 2015;149:124-38.
16. Fan J, Zhao Y, Yuan H, Yang J, Li T, He Z, et al. Phospholipase C-epsilon regulates bladder cancer cells via ATM/EXO1. American journal of cancer research. 2020;10(8):2319-36.
17. Tomimatsu N, Mukherjee B, Harris JL, Boffo FL, Hardebeck MC, Potts PR, et al. DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair. The Journal of biological chemistry. 2017;292(26):10779-90.
18. Mei Z, Zhang D, Hu B, Wang J, Shen X, Xiao W. FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity. The Journal of biological chemistry. 2015;290(26):16202-14.
19. Yang C, Fan P, Zhu S, Yang H, Jin X, Wu H. 3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer. Oncology letters. 2018;15(6):8878-84.
20. Lu Y, Cao G, Lan H, Liao H, Hu Y, Feng H, et al. Chondrocyte-derived Exosomal miR-195 Inhibits Osteosarcoma Cell Proliferation and Anti-Apoptotic by Targeting KIF4A in vitro and in vivo. Translational oncology. 2022;16:101289.
21. Huang P, Liao R, Chen X, Wu X, Li X, Wang Y, et al. Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer. Theranostics. 2020;10(10):4644-58.
22. Gatzka M, Prisco M, Baserga R. Stabilization of the Ras oncoprotein by the insulin-like growth factor 1 receptor during anchorage-independent growth. Cancer Res. 2000;60(15):4222-30.
23. Habel N, El-Hachem N, Soysouvanh F, Hadhiri-Bzioueche H, Giuliano S, Nguyen S, et al. FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells. Cell death and differentiation. 2021;28(6):1837-48.
24. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991-5.
25. Jacob JA. Researchers Turn to Canine Clinical Trials to Advance Cancer Therapies. Jama. 2016;315(15):1550-2.
26. Desai A, Qing Y, Gerson SL. Exonuclease 1 is a critical mediator of survival during DNA double strand break repair in nonquiescent hematopoietic stem and progenitor cells. Stem cells. 2014;32(2):582-93.
27. Dherin C, Gueneau E, Francin M, Nunez M, Miron S, Liberti SE, et al. Characterization of a highly conserved binding site of Mlh1 required for exonuclease I-dependent mismatch repair. Molecular and cellular biology. 2009;29(3):907-18.
28. He D, Li T, Sheng M, Yang B. Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer. Medical science monitor : international medical journal of experimental and clinical research. 2020;26:e918751.
29. Sousa JF, Serafim RB, Freitas LM, Fontana CR, Valente V. DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance. 2019;43(1 suppl 1):e20190066.
30. Bologna S, Altmannova V, Valtorta E, Koenig C, Liberali P, Gentili C, et al. Sumoylation regulates EXO1 stability and processing of DNA damage. Cell cycle. 2015;14(15):2439-50.
31. Kansara M, Leong HS, Lin DM, Popkiss S, Pang P, Garsed DW, et al. Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. The Journal of clinical investigation. 2013;123(12):5351-60.
32. Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, et al. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Laboratory investigation; a journal of technical methods and pathology. 2010;90(3):414-25.
33. Guo W, Zhang M, Shen S, Guo Y, Kuang G, Yang Z, et al. Aberrant methylation and decreased expression of the TGF-beta/Smad target gene FBXO32 in esophageal squamous cell carcinoma. Cancer. 2014;120(16):2412-23.
34. Wang X, Qin G, Liang X, Wang W, Wang Z, Liao D, et al. Targeting the CK1alpha/CBX4 axis for metastasis in osteosarcoma. Nature communications. 2020;11(1):1141.